Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
Zevra Therapeutics revealed that the US Food and Drug Administration (FDA) has indicated it will convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee (GeMDAC) on August 2, 2024, to review the New Drug Application (NDA) for arimoclomol. 15 July 2024
Madrigal Pharmaceuticals, a US biopharma pursuing new therapeutics for non-alcoholic steatohepatitis (NASH), has announced the pricing of its underwritten public offering. 2 October 2023
US health technology assessor the Institute for Clinical and Economic Review (ICER) today posted a Special Report evaluating the evidence on Eliquis (apixaban) and Xarelto (rivaroxaban) for the treatment of non-valvular atrial fibrillation (NVAF). 2 October 2023
Swiss pharma giant Novartis has announced positive top-line results from the pre-specified interim analysis of the Phase III APPLAUSE-IgAN study at nine months. 2 October 2023
ModeX Therapeutics, an OPKO Health company, has received a sizeable grant of up to $168 million from the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Administration for Strategic Preparedness and Response at the US Department of Health and Human Services. 2 October 2023
Addressing what has been dubbed the ‘triple A’ challenge of access, affordability and availability has been an objective of the European Medicines Agency (EMA) for nearly 30 years, going back to the launch of the centralized procedure in 1995. 29 September 2023
Israel and USA-based artificial intelligence (AI) company Quris-AI says that it has agreed to expand its existing partnership with Germany’s Merck KGaA. 29 September 2023
US financial services company Morningstar has published its Biopharma Pipeline Report which provides a five-year outlook on key trends in the space, as well as an in-depth review of pipelines and major therapeutic areas. 29 September 2023
The UK pharma industry has responded to proposed changes to the statutory scheme for branded medicines, arguing against their implementation. 29 September 2023
Karuna Therapeutics has taken a significant step with its submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for KarXT (xanomeline-trospium), its ground-breaking product aiming to revolutionize the treatment of schizophrenia. 28 September 2023
Ophthalmic company Ocuphire Pharma, a specialist in retinal and refractive eye disorders, together with partner Viatris, have secured US approval for Ryzumvi (phentolamine). 27 September 2023
US biopharma Soleno Therapeutics saw its market capitalization leap five-fold yesterday, with the shares hitting $26.80, after it announced promising research results for its lead pipeline candidate, which has encountered previous setbacks. 27 September 2023
USA-based Ionis Pharmaceuticals yesterday released positive top-line results for the Phase III Balance study of olezarsen in people with familial chylomicronemia syndrome (FCS), a rare genetic disorder. 27 September 2023
Molnupiravir, an antiviral treatment for COVID-19 marketed by US pharma giant Merck & Co under the name Lagevrio, could in fact lead to the virus mutating, according to a research article. 26 September 2023
A $250 million private financing for California’s BridgeBio Pharma will support a possible launch of acoramidis, as well as further late-stage pipeline development. 26 September 2023
Australian dermatology company Botanix today revealed it has received a communication from the US Food and Drug Administration (FDA) in relation to its New Drug Application (NDA) submission for sofpironium bromide (SB) gel, 15%. 26 September 2023
Danish company Acesion Pharma has closed an oversubscribed Series B financing round, raising around 43 million euros ($48 million) to support its work in atrial fibrillation (AF). 26 September 2023
Danish drugmaker Novo Nordisk and Valo Health have entered into an agreement to discover and develop novel treatments for cardiometabolic diseases. 25 September 2023
Research is repeatedly showing that co-administration of individual drugs as combination therapy offers significant benefits to patients. 25 September 2023
Continuing its recent strong investment in the area of oncology, French privately-held company Pierre Fabre has inked a new drug discovery deal with British firm Vernalis. 25 September 2023